Bioventix Announces Patent Opposition

Bioventix plc ("Bioventix" or the "Company") Bioventix Announces Patent Opposition It has come to the Company's attention that DiaSource ImmunoAssays S.A. of Belgium ("DiaSource") has recently been granted a European patent in the field of anti vitamin D antibodies and their use in assays (i.e. tests) for vitamin D sufficiency and deficiency. After having taken legal and patent advice from the Company's advisors, the Company is taking action to vigorously oppose this particular patent granted to DiaSource. Peter Harrison, CEO of Bioventix plc said "We are vigilant in monitoring patent property that could potentially impact on our business and this patent relating to anti-vitamin D antibodies is relevant to us. After having taken advice from our patent agents and patent lawyers on the strength of our position, we have taken the decision to commence formal proceedings directed towards the validity of certain claims in this patent." For further information please contact: Bioventix plc Chief Executive Officer Tel: 01252 728 001 Peter Harrison finnCap Ltd Corporate Finance Tel: 020 7220 0500 Geoff Nash/Simon Hicks Corporate Broking Steve Norcross About Bioventix plc: Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on ISDX under the symbol BVXP.